Accelerating DoD’s Fielding of Prototypes for
Medical Countermeasures
NEW BUSINESS OPPORTUNITIES
New RPP Released:
New Draft SOO Released:
DRAFT SOO: UPREG
DRAFT SOO: Operationalizing Novel Technologies for Advanced Rapid Generation of Effective MCMs (ONTARGET)
DRAFT SOO: Assay Expansion for Chemical Diagnostics System (AECDS)
DRAFT SOO: Increased Micro Sampling to Monitor Immunological Response (IMMIR)
DRAFT SOO: Rapid Antigen Identification and Immunogenic Characterization (RAIIC)
New RFIs Released:
RFI: Host Directed Therapeutics
RFI: Immune Microphysiological Systems (IMPS)
MCDC offers a wide variety of
members and funding opportunities
Current Members
Awards
Funded to Date
Non-Traditional Members
The Medical CBRN Defense Consortium (MCDC) was formed in response to the Government’s expressed interest to establish an Other Transaction Agreement (OTA) with an eligible entity or group of entities, to include industry, academic, and not-for-profit partners, for advanced development efforts to support the Department of Defense’s (DoD) medical pharmaceutical and diagnostic requirements as related to enhancing the mission effectiveness of military personnel.
WHO CAN JOIN?
Companies that are part of the US Industrial base, as well as new and emerging non-traditional defense contractors, are encouraged to join the MCDC and participate in Federally-funded R&D projects.
• Traditional Contractors
• Non-Traditionals (Companies that don’t typically participate in Federal R&D)
• Academia
• Non-Profit/Not-For-Profit Research Institutions
PREVENTION
Prophylaxis, pretreatment, and post-exposure prophylaxis
DIAGNOSTICS
Systems and devices to identify CBRN agents and assist in making medical decisions
TREATMENT
Therapeutics for post-exposure and post-symptomatic
Led by
MCDC research and prototype work is executed by project teams from a broad-based industry/academia collaboration.
Sponsored by
Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
Managed by
